Skip to content

Elite Pharmaceuticals, Inc.: 10-Q filed 2024-02-14

What Elite Pharmaceuticals, Inc. reported in its quarterly report filed 2024-02-14 (fiscal Q3 2024): 49 published measures, 144 facts as tagged in accession 0001493152-24-006661.

This filing

Form
10-Q (quarterly report)
Filed
2024-02-14
Fiscal period
fiscal Q3 2024
Accession
0001493152-24-006661 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Elite Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-12-3174,696,279USD
At 2023-03-3140,896,018USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-12-3128,282,558USD
At 2023-03-3111,935,758USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-12-3146,413,721USD
At 2023-09-3045,094,447USD
At 2023-06-3030,117,069USD
At 2023-03-3128,960,260USD
At 2022-12-3130,174,514USD
At 2022-09-3027,191,407USD
At 2022-06-3025,533,232USD
At 2022-03-3125,222,027USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2023-12-315,816,211USD
At 2023-03-317,832,247USD
At 2022-12-3117,909,077USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-10-01 to 2023-12-31706,354USD92
2023-04-01 to 2023-12-3116,782,764USD275
2023-07-01 to 2023-09-3014,934,601USD92
2023-04-01 to 2023-06-301,141,809USD91
2022-10-01 to 2022-12-312,970,078USD92
2022-04-01 to 2022-12-314,791,100USD275
2022-07-01 to 2022-09-301,515,139USD92
2022-04-01 to 2022-06-30305,883USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-04-01 to 2023-12-31-5,341,537USD275
2022-04-01 to 2022-12-31370,021USD275

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2023-04-01 to 2023-12-31406,007USD275
2022-04-01 to 2022-12-315,200,407USD275

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2023-10-01 to 2023-12-3115,538,800USD92
2023-04-01 to 2023-12-3138,676,061USD275
2022-10-01 to 2022-12-319,250,066USD92
2022-04-01 to 2022-12-3125,513,551USD275

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-04-01 to 2023-12-313,747,073USD275
2022-04-01 to 2022-12-3114,204,231USD275

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-04-01 to 2023-12-31-406,007USD275
2022-04-01 to 2022-12-31-5,200,407USD275

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-12-31-119,715,134USD
At 2023-03-31-136,497,898USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2023-10-01 to 2023-12-311,014,768,071shares92
2023-04-01 to 2023-12-311,014,265,162shares275
2022-10-01 to 2022-12-311,013,915,081shares92
2022-04-01 to 2022-12-311,012,480,115shares275

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2023-10-01 to 2023-12-311,024,448,445shares92
2023-04-01 to 2023-12-311,019,511,813shares275
2022-10-01 to 2022-12-311,013,915,081shares92
2022-04-01 to 2022-12-311,012,480,115shares275

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2023-10-01 to 2023-12-310USD/shares92
2023-04-01 to 2023-12-310.02USD/shares275
2022-10-01 to 2022-12-310USD/shares92
2022-04-01 to 2022-12-310USD/shares275

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2023-10-01 to 2023-12-310USD/shares92
2023-04-01 to 2023-12-310.02USD/shares275
2022-10-01 to 2022-12-310USD/shares92
2022-04-01 to 2022-12-310.01USD/shares275

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2023-10-01 to 2023-12-31-800,613USD92
2023-04-01 to 2023-12-31-18,313,045USD275
2022-10-01 to 2022-12-3139,250USD92
2022-04-01 to 2022-12-3150,837USD275

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2023-12-3110,095,029USD
At 2023-03-3110,426,158USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-10-01 to 2023-12-313,532,656USD92
2023-04-01 to 2023-12-317,060,185USD275
2022-10-01 to 2022-12-311,959,100USD92
2022-04-01 to 2022-12-314,062,901USD275

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-12-3137,156,502USD
At 2023-03-3121,510,297USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2023-10-01 to 2023-12-31121,628USD92
2023-04-01 to 2023-12-31371,478USD275
2022-10-01 to 2022-12-31322,681USD92
2022-04-01 to 2022-12-31782,221USD275

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-12-3119,158,799USD
At 2023-03-317,833,637USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2023-12-312,890,717USD
At 2023-03-312,446,810USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2023-12-316,341,228USD
At 2023-03-316,341,228USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2023-12-3116,009,614USD
At 2023-03-313,094,549USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2023-10-01 to 2023-12-313,508,417USD92
2023-04-01 to 2023-12-3111,178,522USD275
2022-10-01 to 2022-12-312,960,125USD92
2022-04-01 to 2022-12-319,089,715USD275

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2023-12-3114,325,041USD
At 2023-03-319,550,716USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2023-10-01 to 2023-12-317,041,073USD92
2023-04-01 to 2023-12-3118,238,707USD275
2022-10-01 to 2022-12-314,919,225USD92
2022-04-01 to 2022-12-3113,152,616USD275

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2023-10-01 to 2023-12-318,497,727USD92
2023-04-01 to 2023-12-3120,437,354USD275
2022-10-01 to 2022-12-314,330,841USD92
2022-04-01 to 2022-12-3112,360,935USD275

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-10-01 to 2023-12-311,403,790USD92
2023-04-01 to 2023-12-315,165,684USD275
2022-10-01 to 2022-12-311,443,361USD92
2022-04-01 to 2022-12-313,775,107USD275

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2023-12-311,017,781,199shares
At 2023-03-311,013,915,081shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2023-12-316,244,210USD
At 2022-12-3118,314,241USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2023-12-31165,417,811USD
At 2023-03-31164,750,980USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2023-12-3126,231USD
At 2023-03-3113,062USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2023-12-3126,230USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2023-12-3125,673,500USD
At 2023-03-3125,012,493USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2023-12-3115,578,471USD
At 2023-03-3114,586,335USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2023-12-3111,884,645USD
At 2023-03-315,047,726USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2023-12-311,005,636USD
At 2023-03-311,032,785USD

Current contract liabilities

Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.

PeriodValueUnitDays
At 2023-12-3113,333USD
At 2023-03-3113,333USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2023-10-01 to 2023-12-31-94,259USD92
2023-04-01 to 2023-12-31-1,530,281USD275
2022-10-01 to 2022-12-313,009,328USD92
2022-04-01 to 2022-12-314,841,937USD275

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2023-10-01 to 2023-12-31706,354USD92
2023-04-01 to 2023-12-3116,782,764USD275
2022-10-01 to 2022-12-312,970,078USD92
2022-04-01 to 2022-12-314,791,100USD275

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2023-10-01 to 2023-12-311,711,275USD92
2023-04-01 to 2023-12-314,906,187USD275
2022-10-01 to 2022-12-311,186,049USD92
2022-04-01 to 2022-12-314,356,752USD275

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2023-10-01 to 2023-12-31336,614USD92
2023-04-01 to 2023-12-31992,136USD275
2022-10-01 to 2022-12-31314,610USD92
2022-04-01 to 2022-12-31923,365USD275

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2023-04-01 to 2023-12-31992,136USD275
2022-04-01 to 2022-12-31933,531USD275

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2023-10-01 to 2023-12-31-3,626,915USD92
2023-04-01 to 2023-12-31-8,590,466USD275
2022-10-01 to 2022-12-311,050,228USD92
2022-04-01 to 2022-12-31779,036USD275

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2023-04-01 to 2023-12-31119,412USD275
2022-04-01 to 2022-12-31782,221USD275

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2023-04-01 to 2023-12-31292,000USD275
2022-04-01 to 2022-12-31127,522USD275

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2023-04-01 to 2023-12-3113,109,665USD275
2022-04-01 to 2022-12-312,487,930USD275

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2023-04-01 to 2023-12-314,774,325USD275
2022-04-01 to 2022-12-311,860,688USD275

Inspect the source

Entity
Elite Pharmaceuticals, Inc. / CIK 0001053369
Captured
2026-09-20T05:17:33.154Z
SEC response SHA-256
b91e0331a01f96870ee44e841f605bd504e1bc784022b77f374cfe93dc363314

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001053369.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))